Entrada Therapeutics, Inc. (TRDA) Stock Profile — Insider Trades & Financials

Revenue$1.3M

Net Income-$39.2M

EPS$-3.47

Market Cap$548.2M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Dipal Doshi

CEO & Executive Director

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Companyâs Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Founded: 2016
Employees: 152
Headquarters

⚡

Core Efficiency

ROE?

-12.79%

ROA?

-10.38%

D/E Ratio?

0.23

Op. Margin?

-3249.27%

📊

Profitability Ratios

Net Margin?

-3014.93%

Loading company sections...

Entrada Therapeutics, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness